PortalPublikationenPresence of EpCAM-positive circulating tumor cells as biomar...

Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma

Standard

Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma. / Schulze, Kornelius; Gasch, Christin; Staufer, Katharina; Nashan, Björn; Lohse, Ansgar W; Pantel, Klaus; Riethdorf, Sabine; Wege, Henning.

in: INT J CANCER, Jahrgang 133, Nr. 9, 01.11.2013, S. 2165-71.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Schulze, K, Gasch, C, Staufer, K, Nashan, B, Lohse, AW, Pantel, K, Riethdorf, S & Wege, H 2013, 'Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma', INT J CANCER, Jg. 133, Nr. 9, S. 2165-71. https://doi.org/10.1002/ijc.28230

APA

Schulze, K., Gasch, C., Staufer, K., Nashan, B., Lohse, A. W., Pantel, K., Riethdorf, S., & Wege, H. (2013). Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma. INT J CANCER, 133(9), 2165-71. https://doi.org/10.1002/ijc.28230

Vancouver

Schulze K, Gasch C, Staufer K, Nashan B, Lohse AW, Pantel K et al. Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma. INT J CANCER. 2013 Nov 1;133(9):2165-71. https://doi.org/10.1002/ijc.28230

Bibtex

@article{20087a9499e944ab8cbc18d895fce1b4,
title = "Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma",
abstract = "Current imaging technologies do not sufficiently detect micrometastasis and therefore do not allow adequate stratification of patients with hepatocellular carcinoma (HCC) for curative or systemic therapy. In HCC, presence of stem cell-like, epithelial cell adhesion molecule (EpCAM)-positive cells correlates with tumor aggressiveness and formation of metastasis. Therefore, we investigated the prognostic relevance of EpCAM-positive circulating tumor cells (CTCs) in patients with HCC. Blood from 78 patients (19 patients in the control cohort and 59 patients with HCC) was tested for CTCs with the CellSearch{\texttrademark} system. Correlation analysis to overall survival (OS), the Barcelona Clinic Liver Cancer (BCLC) staging system, macroscopic and microscopic vascular invasion and alpha-fetoprotein (AFP) levels were performed. We detected ≥1 CTC in 18/59 HCC patients and in 1/19 patients with cirrhosis or benign hepatic tumor (p = 0.026). OS was significantly shorter (460 vs. 746 days) in the CTC-positive cohort (p = 0.017). Comparing BCLC stages, significant differences in CTC detection rates were also observed: BCLC stages A 1/9, B 6/31 and C 11/19 (p = 0.006). Ten of 18 patients with macroscopic and 10/16 patients with microscopic vascular invasion exhibited positive findings in CTC testing (p = 0.004 and p = 0.006). Furthermore, CTC results correlated to AFP (cutoff > 400 ng/mL) levels (p = 0.050). Our study demonstrates frequent presence of EpCAM-positive CTC in patients with intermediate or advanced HCC and its prognostic value for OS with possible implications for future treatment stratification.",
keywords = "Adult, Aged, Aged, 80 and over, Antigens, Neoplasm, Carcinoma, Hepatocellular, Case-Control Studies, Cell Adhesion Molecules, Female, Follow-Up Studies, Humans, Liver Neoplasms, Male, Microscopy, Fluorescence, Middle Aged, Neoplasm Invasiveness, Neoplasm Staging, Neoplastic Cells, Circulating, Prognosis, Prospective Studies, Survival Rate, Tumor Markers, Biological",
author = "Kornelius Schulze and Christin Gasch and Katharina Staufer and Bj{\"o}rn Nashan and Lohse, {Ansgar W} and Klaus Pantel and Sabine Riethdorf and Henning Wege",
note = "Copyright {\textcopyright} 2013 UICC.",
year = "2013",
month = nov,
day = "1",
doi = "10.1002/ijc.28230",
language = "English",
volume = "133",
pages = "2165--71",
journal = "INT J CANCER",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "9",

}

RIS

TY - JOUR

T1 - Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma

AU - Schulze, Kornelius

AU - Gasch, Christin

AU - Staufer, Katharina

AU - Nashan, Björn

AU - Lohse, Ansgar W

AU - Pantel, Klaus

AU - Riethdorf, Sabine

AU - Wege, Henning

N1 - Copyright © 2013 UICC.

PY - 2013/11/1

Y1 - 2013/11/1

N2 - Current imaging technologies do not sufficiently detect micrometastasis and therefore do not allow adequate stratification of patients with hepatocellular carcinoma (HCC) for curative or systemic therapy. In HCC, presence of stem cell-like, epithelial cell adhesion molecule (EpCAM)-positive cells correlates with tumor aggressiveness and formation of metastasis. Therefore, we investigated the prognostic relevance of EpCAM-positive circulating tumor cells (CTCs) in patients with HCC. Blood from 78 patients (19 patients in the control cohort and 59 patients with HCC) was tested for CTCs with the CellSearch™ system. Correlation analysis to overall survival (OS), the Barcelona Clinic Liver Cancer (BCLC) staging system, macroscopic and microscopic vascular invasion and alpha-fetoprotein (AFP) levels were performed. We detected ≥1 CTC in 18/59 HCC patients and in 1/19 patients with cirrhosis or benign hepatic tumor (p = 0.026). OS was significantly shorter (460 vs. 746 days) in the CTC-positive cohort (p = 0.017). Comparing BCLC stages, significant differences in CTC detection rates were also observed: BCLC stages A 1/9, B 6/31 and C 11/19 (p = 0.006). Ten of 18 patients with macroscopic and 10/16 patients with microscopic vascular invasion exhibited positive findings in CTC testing (p = 0.004 and p = 0.006). Furthermore, CTC results correlated to AFP (cutoff > 400 ng/mL) levels (p = 0.050). Our study demonstrates frequent presence of EpCAM-positive CTC in patients with intermediate or advanced HCC and its prognostic value for OS with possible implications for future treatment stratification.

AB - Current imaging technologies do not sufficiently detect micrometastasis and therefore do not allow adequate stratification of patients with hepatocellular carcinoma (HCC) for curative or systemic therapy. In HCC, presence of stem cell-like, epithelial cell adhesion molecule (EpCAM)-positive cells correlates with tumor aggressiveness and formation of metastasis. Therefore, we investigated the prognostic relevance of EpCAM-positive circulating tumor cells (CTCs) in patients with HCC. Blood from 78 patients (19 patients in the control cohort and 59 patients with HCC) was tested for CTCs with the CellSearch™ system. Correlation analysis to overall survival (OS), the Barcelona Clinic Liver Cancer (BCLC) staging system, macroscopic and microscopic vascular invasion and alpha-fetoprotein (AFP) levels were performed. We detected ≥1 CTC in 18/59 HCC patients and in 1/19 patients with cirrhosis or benign hepatic tumor (p = 0.026). OS was significantly shorter (460 vs. 746 days) in the CTC-positive cohort (p = 0.017). Comparing BCLC stages, significant differences in CTC detection rates were also observed: BCLC stages A 1/9, B 6/31 and C 11/19 (p = 0.006). Ten of 18 patients with macroscopic and 10/16 patients with microscopic vascular invasion exhibited positive findings in CTC testing (p = 0.004 and p = 0.006). Furthermore, CTC results correlated to AFP (cutoff > 400 ng/mL) levels (p = 0.050). Our study demonstrates frequent presence of EpCAM-positive CTC in patients with intermediate or advanced HCC and its prognostic value for OS with possible implications for future treatment stratification.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Antigens, Neoplasm

KW - Carcinoma, Hepatocellular

KW - Case-Control Studies

KW - Cell Adhesion Molecules

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Liver Neoplasms

KW - Male

KW - Microscopy, Fluorescence

KW - Middle Aged

KW - Neoplasm Invasiveness

KW - Neoplasm Staging

KW - Neoplastic Cells, Circulating

KW - Prognosis

KW - Prospective Studies

KW - Survival Rate

KW - Tumor Markers, Biological

U2 - 10.1002/ijc.28230

DO - 10.1002/ijc.28230

M3 - SCORING: Journal article

C2 - 23616258

VL - 133

SP - 2165

EP - 2171

JO - INT J CANCER

JF - INT J CANCER

SN - 0020-7136

IS - 9

ER -